Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lise Tarnow

Showing results (71-80 of 187) with videos related to

Pageof 19
Sort By:
Journal of Diabetes|May 1, 2016
Prediction of excessive weight gain in insulin treated patients with type 2 diabetesSimon Lebech Cichosz, Louise Lundby-Christensen, Mette D Johansen, et al.
Kidney International|May 23, 2008
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathyAnders Jorsal, Lise Tarnow, Jan Frystyk, et al.
Endocrine Connections|May 10, 2015
Vitamin D, carotid intima-media thickness and bone structure in patients with type 2 diabetesKaroline Winckler, Lise Tarnow, Louise Lundby-Christensen, et al.
Diabetes Care|March 29, 2003
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetesPeter Hovind, Lise Tarnow, Kasper Rossing, et al.
Kidney International|December 1, 2005
Beneficial impact of spironolactone in diabetic nephropathyKatrine Jordan Schjoedt, Kasper Rossing, Tina Ragnholm Juhl, et al.
Ugeskrift for Laeger|September 10, 2010
[Reporting adverse reactions and events in randomised clinical trials]Bianca Hemmingsen, Lina Støy, Jørn Wetterslev, et al.
BMJ (Clinical Research Ed.)|April 21, 2004
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort studyPeter Hovind, Lise Tarnow, Peter Rossing, et al.
Journal of Negative Results in Biomedicine|May 10, 2011
The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetesAmélie Dendooven, Tri Q Nguyen, Lodewijk Brosens, et al.
Seminars in Nephrology|March 16, 2004
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end pointsHans-Henrik Parving, Steen Andersen, Peter Jacobsen, et al.
Current Medical Research and Opinion|June 22, 2016
Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemiaUlrik Pedersen-Bjergaard, Peter Lommer Kristensen, Kirsten Nørgaard, et al.
Pageof 19

Showing results (71-80 of 187) with videos related to

Sort By:
Pageof 19
Journal of Diabetes|May 1, 2016
Prediction of excessive weight gain in insulin treated patients with type 2 diabetesSimon Lebech Cichosz, Louise Lundby-Christensen, Mette D Johansen, et al.
Kidney International|May 23, 2008
Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathyAnders Jorsal, Lise Tarnow, Jan Frystyk, et al.
Endocrine Connections|May 10, 2015
Vitamin D, carotid intima-media thickness and bone structure in patients with type 2 diabetesKaroline Winckler, Lise Tarnow, Louise Lundby-Christensen, et al.
Diabetes Care|March 29, 2003
Decreasing incidence of severe diabetic microangiopathy in type 1 diabetesPeter Hovind, Lise Tarnow, Kasper Rossing, et al.
Kidney International|December 1, 2005
Beneficial impact of spironolactone in diabetic nephropathyKatrine Jordan Schjoedt, Kasper Rossing, Tina Ragnholm Juhl, et al.
Ugeskrift for Laeger|September 10, 2010
[Reporting adverse reactions and events in randomised clinical trials]Bianca Hemmingsen, Lina Støy, Jørn Wetterslev, et al.
BMJ (Clinical Research Ed.)|April 21, 2004
Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort studyPeter Hovind, Lise Tarnow, Peter Rossing, et al.
Journal of Negative Results in Biomedicine|May 10, 2011
The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetesAmélie Dendooven, Tri Q Nguyen, Lodewijk Brosens, et al.
Seminars in Nephrology|March 16, 2004
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end pointsHans-Henrik Parving, Steen Andersen, Peter Jacobsen, et al.
Current Medical Research and Opinion|June 22, 2016
Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemiaUlrik Pedersen-Bjergaard, Peter Lommer Kristensen, Kirsten Nørgaard, et al.
Pageof 19